New immunomodulating drugs in treating moderate to severe psoriasis.
Favorable effects on skin lesions and quality of life in patients with moderate to severe plaque psoriasis have been shown after treatment with infliximab, etanercept and efalizumab for 3 to 6 months (strong scientific evidence). The scientific evidence is insufficient to assess the long-term effect...
Saved in:
| Online Access: |
Full text |
|---|---|
| Format: | Electronic eBook |
| Language: | English |
| Published: |
Stockholm, Sweden :
SBU-Swedish Council on Health Technology Assessment,
2006
|
| Series: | SBU alert report ;
no. 2006-07. |
| Subjects: |
